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Highlights 
 
 ▪ Several metabolites and specific pathway are altered in the hippocampus by SF.  
 ▪ The metabolite profiles vary according to the duration of SF.  
 ▪ The alanine, aspartate, and glutamate metabolism pathway is the most altered 
pathway.  
 
 
Abstract 
Sleep fragmentation (SF) commonly occurs in several pathologic conditions and is especially 
associated with impairments of hippocampus-dependent neurocognitive functions. Although 
the effects of SF on hippocampus in terms of protein or gene levels were examined in several 
studies, the impact of SF at the metabolite level has not been investigated. Thus, in this study, 
the differentially expressed large-scale metabolite profiles of hippocampus in a rat model of 
SF were investigated using untargeted metabolomics approaches. Forty-eight rats were 
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divided into the following 4 groups: 4-day SF group, 4-day exercise control (EC) group, 15-
day SF group, and 15-day EC group (n=12, each). SF was accomplished by forced exercise 
using a walking wheel system with 30-s on/90-s off cycles, and EC condition was set at 10-
min on/30-min off. The metabolite profiles of rat hippocampi in the SF and EC groups were 
analyzed using liquid chromatography/mass spectrometry. Multivariate analysis revealed 
distinctive metabolic profiles and marker signals between the SF and corresponding EC 
groups. Metabolic changes were significant only in the 15-day SF group. In the 15-day SF 
group, L-tryptophan, myristoylcarnitine, and palmitoylcarnitine were significantly increased, 
while adenosine monophosphate, hypoxanthine, L-glutamate, L-aspartate, L-methionine, and 
glycerophosphocholine were decreased compared to the EC group. The alanine, aspartate, 
and glutamate metabolism pathway was observed as the common key pathway in the 15-day 
SF groups. The results from this untargeted metabolomics study provide a perspective on 
metabolic impact of SF on the hippocampus.  
 
Word count: 234 
Keywords: sleep fragmentation, hippocampus, untargeted metabolomics, exercise control, 
metabolites  
 
 
 
 
1. Introduction 
Sleep is an essential process, and appropriate amounts of sleep are necessary to achieve 
normal body function. However, mounting evidence has shown that sleep continuity is also 
important for health, and decreased sleep continuity has been associated with several 
pathologic symptoms (e.g., increased inflammatory cytokines, elevated blood pressure, and 
impaired neurocognitive functions) and risk of chronic disease such as diabetes or 
cardiovascular disease (Dumaine and Ashley, 2015; Ekstedt et al., 2004; Qian et al., 2016; 
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Ramesh et al., 2012). Sleep fragmentation (SF), defined as brief arousals that occur during 
sleep, can be induced by external factors such as bright light, high temperature or humidity, 
and noise during sleep. Moreover, it occurs frequently in patients with sleep apnea, chronic 
pain (Blagestad et al., 2012), periodic leg movements(Mancebo-Sosa et al., 2016), and 
asthma (Luyster et al., 2012). SF causes excessive daytime sleepiness (EDS), possibly by 
inhibiting cholinergic neuronal activity in the basal forebrain and elevating adenosine level 
(McKenna et al., 2007). EDS increases the risk of motor vehicle accidents (Ward et al., 2013) 
and decreases daytime functioning (Gooneratne et al., 2003; Stepanski, 2002). In addition, 
EDS is strongly associated with incident cardiovascular morbidity and mortality (Newman et 
al., 2000).  
The hippocampus is a brain structure especially vulnerable to sleep disturbance in 
terms of morphological and functional aspects. In a recent experimental study, chronic sleep 
restriction (SR) resulted in a 10% reduction in hippocampal volume in rats, without an 
overall decrease in cortical thickness compared with controls (Novati et al., 2011). Human 
neuroimaging studies that examined the association between short sleep or disturbed sleep 
and hippocampal volume showed similar findings to those reported in animal studies (Joo et 
al., 2014; Taki et al., 2012). In animal studies, SF resulted in hippocampus-dependent 
learning and cognition deficits (Nair et al., 2011; Sportiche et al., 2010; Tartar et al., 2006). 
However, the appearance of negative impacts of SF varies depending on the duration of SF 
(Wallace et al., 2015). The possible mechanisms by which SF induces impairments include 
reduction in hippocampal neurogenesis (Guzman-Marin et al., 2007; Sportiche et al., 2010), 
increase of reactive oxygen species through upregulation and activation of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, and loss of N-methyl-D-aspartate 
(NMDA) receptor-dependent long-term potentiation in hippocampal area CA1 (Tartar et al., 
2010; Tartar et al., 2006).  
Metabolomics is an emerging field of ‘omics’ research for global or system-wide 
metabolite profiles under a given set of conditions (Goodacre et al., 2004; Wishart, 2008), 
using analytical chemistry techniques such as nuclear magnetic resonance (NMR), 
chromatography, and mass spectrometry (MS)(Azad and Shulaev, 2018; Zhang et al., 2012). 
This field of research promises a better understanding of the pathophysiology of several 
chronic diseases and development of potential biomarkers (Ivanisevic and Thomas, 2018). 
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Metabolomics has also been used for therapeutic monitoring and development of drugs 
(Puchades-Carrasco and Pineda-Lucena, 2017; Wei, 2011). Metabolomics is divided into two 
approaches (Patti et al., 2012), targeted and untargeted. Targeted metabolomics attempts to 
identify or quantitate defined individual metabolites (Roberts et al., 2012), whereas 
untargeted metabolomics investigates comprehensive profiles of all measurable metabolites 
using high-throughput methods (Vinayavekhin and Saghatelian, 2010).  
Molecular changes caused by SF or sleep deprivation (SD) in genes and protein levels 
of rodent brains have been previously investigated. Reportedly, genes or proteins associated 
with cellular response to stress, energy metabolism, neuronal transmission, and synaptic 
plasticity were altered by SF or SD (Cirelli, 2006; Franco-Perez et al., 2012; Guzman-Marin 
et al., 2006). However, previous studies have several weaknesses regarding use of the 
appropriate animal model and limited methodologies. First, occurrence of long-term SD in 
humans is rare. Second, high-throughput gene expression analysis approaches cannot predict 
a post-translational modification of proteins, complicating direct interpretation of the function 
of expressed genes. Third, specific types of proteins are difficult to analyze using proteomic 
technologies (Chandramouli and Qian, 2009). However, alteration of metabolites reflect the 
actual activity of the cells; thus, the changes in the metabolome are more amplified than those 
in the transcriptome and the proteome (Urbanczyk-Wochniak et al., 2003). Moreover, the 
metabolome shows greater diversity and thus is closer to the phenotype of the biological 
system than the transcriptome and the proteome (Horgan et al., 2009). Therefore, in the 
present study, the changes of metabolites in the hippocampus, a brain region vulnerable to 
sleep disturbance, were investigated using untargeted metabolomics. This approach could 
provide a better understanding of the hippocampus including pathophysiology of 
hippocampus-dependent learning and cognitive impairments subjected to SF in terms of 
individual metabolites or specific metabolic pathways.    
In this study, 4-day and 15-day SF models were used and the metabolite profiles were 
compared to the corresponding exercise control groups. We considered both the 
chronological criteria and the periods in which appropriate phenotypes can be expressed 
based on previous studies to determine the appropriate duration of the experiment. In terms of 
duration, acute SF generally refers to a one-night or several-night period in which sleep is 
interrupted, while chronic SF refers to a relatively long period of interrupted sleep (weeks or 
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months). Indeed, electrophysiological data show that acute SF is different from chronic SF. 
Another study, with a different duration from our experimental period, have shown distinct 
effects on non-rapid eye movement (NREM) and rapid eye movement (REM) bout length 
during recovery periods in 3-day (acute) and 14-day (chronic) sleep-fragmented mice 
(Wallace et al., 2015). Other studies have also shown that 4-day and 15-day SF caused a 
reduction in hippocampal neurogenesis (Guzman-Marin et al., 2007) and deficits in 
hippocampus-dependent cognitive function (Nair et al., 2011), respectively. Thus, we chose 
4-day and 15-day to distinguish the acute and chronic effects of SF on biochemical changes 
in hippocampus.     
  
2. Materials and Methods 
2.1 Animals 
Seven-week-old male Wistar rats (Orient Bio, Korea) weighing 210–230 g were used 
in this study. Animals were maintained in a temperature-controlled room (24 ± 2oC) with 
alternating 12-h light and 12-h dark cycles (lights on at 8:00 a.m.) The rats had free access to 
food and water. After the 1-week acclimatization period, 48 rats were randomly divided into 
the following four groups: 4-day SF group (n=12), 4-day exercise control (EC) group (n=12), 
15-day SF group (n=12), and 15-day EC group (n=12). All experimental procedures 
involving animals were performed in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the 
Korea University College of Medicine (KUIACUC-2012-148).  
 
2.2 Sleep recording and analysis 
In separate experiments, electroencephalography (EEG) was recorded in the 4-day and 
15-day SF and EC groups (n=4, each) to evaluate the suitability of the SF and EC models. 
Two pairs of EEG electrodes were implanted into the frontoparietal and lateral lobes and a 
pair of electromyography (EMG) electrodes (Pinnacle Technology Inc., Lawrence, KS, USA) 
was inserted into the neck muscles of rats. After surgery, the rats were recovered for 7 days. 
The rats were connected to a cable and acclimatized to the processes for 2 days before 
acquisition of baseline data. For 4-day group, we recorded and analyzed 24 hours of EEG and 
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EMG at a sampling rate of 200 Hz on baseline, Day 1, Day 2, Day 3, and Day 4 of SF and EC 
procedures. For the 15-day group, 24 hours of EEG and EMG were recorded at baseline, Day 
7, and on Day 15 of SF and EC procedures. Sleep data were semi-automatically analyzed 
using Sirenia software (Pinnacle Technology Inc., Lawrence, KS, USA), and were then 
confirmed by visual scoring to determine the percentage of sleep time by stage, bout number, 
and bout length. The duration of one epoch was set to 10 seconds. The frequency range for 
each waveform was defined as delta 0.5-4 Hz, theta 4-8 Hz, and alpha 8-13 Hz. A bout was 
defined as at least two consecutive 10-s epochs for a given state and ended with any single 
sate-change epoch.   
 
2.3 Experimental procedures for SF and EC   
Schematic experimental protocols are shown in Figure 1 (Fig. 1A and 1B). The forced 
exercise walking wheel system for rats was used to interrupt sleep in rats (Model number: 
80805A, Lafayette Instruments, Lafayette, IN, USA), a previously validated method for the 
effectiveness of SF in mice (Yoon, 2012). Briefly, the rats were placed in an individual 
motor-driven wheel 7 days before the start of SF or EC procedure to acclimate to the novel 
environment. Experimental conditions for the 4-day and 15-day SF groups were as follows: 
activation time (wheel running): 30 s, stopped time (wheel not running): 90 s, wheel speed: 
4.5 m/min, duration: 24 h/day. The condition consistently produced 30 awakenings per h, 
mimicking arousals observed in severe sleep apnea. To exclude the effects of non-specific 
movement, an additional EC group was used. The conditions for the EC group were 10 min 
on/30 min off, which offers the same amount of walking distance as for the rats in the SF 
group. The rats were weighted at baseline and on the day of sacrifice.   
 
2.4 Sample preparation 
On sacrifice day, the rats were deeply anesthetized using isoflurane and then 
decapitated using a rat guillotine. The hippocampi were excised, immediately snap-frozen in 
liquid nitrogen, and stored at -80℃ until further processing. The frozen hippocampi were cut 
into pieces approximately 0.7–0.8 cm x 1 mm in size using a surgical knife, transferred to a 
mortar chilled using liquid nitrogen, and homogenized. The pulverized samples were 
dissolved using 1.0 mL of cold methanol/acetonitrile/water buffer (5:3:2) and then transferred 
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to 1.5-mL microtubes. The centrifugation was performed at 28,756 g for 20 min at 4oC, and 
the supernatant was centrifuged under the same conditions for an additional 20 min to remove 
particulate matter. The supernatant was dried using a centrifugal concentration system (VS-
802 Centra-vac, Vision Scientific, Bucheon, Korea), and the extract was dissolved in 50 μL 
of methanol/acetonitrile/water buffer (5:3:2). The entire sample preparation was finished in 3 
h. 
 
2.5 Liquid chromatography/MS (LC/MS)  
The liquid chromatography/MS (LC/MS) analysis was performed as previously 
described (Jin et al., 2014). In brief, 5 µL of the dissolved sample was injected into the 
Agilent 1100 series high-performance LC (HPLC) system (Agilent Technologies, Santa Clara, 
CA, USA) coupled with LTQ-XL high performance linear ion trap mass spectrometer 
(Thermo Fisher Scientific Inc., Waltham, MA, USA) equipped with an ESI source. The 
Xcalibur software (Thermo Fisher Scientific Inc.) was used to control chromatographic and 
mass spectral functions. In addition, for further MS/MS analysis, the samples were injected 
into the Agilent 1200 Infinity HPLC system coupled with electrospray ionization (ESI)-
QTOF (Agilent Technologies). A Kinetex C18 column (2.6 µm, 100 × 4.6 mm; Phenomenex, 
Torrance, CA, USA) was maintained at 35oC for chromatographic sample separation. The 
mobile phases were 0.1% formic acid in deionized water (solvent A) and 0.1% formic acid in 
acetonitrile (solvent B). The flow rate of the mobile phase was set at 0.35 mL/min. Analytes 
were eluted with a mobile phase composed of 0.1% formic acid in water (A) and acetonitrile 
with 0.1% formic acid (B). The following gradient conditions were used: 0–14 min gradient 
5–25% B, 14–19 min gradient 25–40% B, and 19–23 min gradient 40–95% B. For 6 min, 95% 
B solvent was maintained to return the gradient to the starting conditions, and column re-
equilibration was performed for 6 min. Data were acquired in positive mode. 
2.6 Data processing, multivariate analysis, marker identification, and pathway analysis  
Before LC/MS data analysis, all metabolites in a sample were divided by the total 
observed number of ions in the sample to normalize the data. The LC/MS data were 
processed with MZmine 2.10 including data conversion and processing as previously 
described (Jin et al., 2014; Pluskal et al., 2010). Briefly, peaks were identified from LC/MS 
chromatograms using the local minimum search function, and a peak list was established by 
grouping ion intensities, matching m/z, and retention time. The peak list was exported to csv 
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form and imported into MetaboAnalyst (Xia et al., 2015). Normalization and peak alignment 
were performed using the sum of all detected peaks, and the processed data were transferred 
into SIMCA-P version 11.0 programs (Umetrics, Umeå, Sweden) for multivariate statistical 
analysis. The principle component analysis (PCA) and the partial least squares discriminant 
analysis (PLS-DA) were performed to determine metabolic differences between the 4-day 
and 15-day SF and EC groups. The orthogonal projections to latent structure discriminant 
analysis (OPLS-DA) were performed to determine whole metabolic differences between EC 
and SF group regardless of experimental times (4-day or 15-day). All multivariate models 
were constructed in an iterative procedure until the predictability value (Q2) did not increase. 
The contributing metabolites for group discrimination were identified by comparing the m/z 
and MS/MS fragmentation patterns from the Human Metabolome Database (www.hmdb.ca), 
METLIN (http://metlin.scripps.edu), and MassBank database (http://www.massbank.jp). 
Metabolic pathway analysis was performed by MetPa analysis through MetaboAnalyst 4.0 
(www.metaboanalyst.ca). 
 
2.7 Statistical analysis  
Differences in body weight and sleep parameters (percent of time spent in each stage, 
bout number, and bout length) between baseline and follow-up period in the same groups 
were determined by paired t-test. Differences in body weight and sleep parameters between 
EC and SF groups were examined by independent t-test for inter-group comparisons. All 
statistical analyses were conducted using SPSS version 20.0 (IBM, Chicago, IL, USA), and 
P<0.05 was considered statistically significant. 
 
 
3. Results 
3.1 Assessment of body weight and the effects of 4 days’ and 15 days’ SF or EC on sleep 
parameters  
Body weight was measured at baseline and on Day 4 (4-day group) or Day 15 (15-day 
group) in the EC and SF groups. 4-day SF group had a slightly lower body weight than the 4-
day EC group on the fourth day of experiment, but the difference was not statistically 
significant (P = 0.054) (Fig. 1C). There was no significant difference in body weight between 
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15-day EC and 15-day SF groups at baseline (P= 0.240) and on Day 15 (P = 0.324) (Fig. 1D). 
Throughout the experimental period of the 4-day group, the percentages of time spent in 
Wake and NREM sleep did not differ significantly between baseline and follow-up or 
between the EC and SF groups (Fig. 1E and 1F). However, the time spent in the REM sleep 
stage was significantly reduced during the entire experiment in the SF group, compared to 
those in the baseline and corresponding EC groups (Fig. 1G). The average Wake and NREM 
bout numbers in the 4-day SF groups were significantly higher than those in the baseline and 
corresponding EC groups throughout the experimental period (Fig. 1H and 1I). However, the 
average NREM bout length decreased in the 4-day SF group on all days of fragmentation, 
compared to the baseline and corresponding EC group (Fig. 1J). In the 15-day group, the 
percentages of time spent in Wake, NREM, and REM sleep did not differ between baseline 
and follow-up or between the EC and SF groups (Fig. 1K-1M). However, the average Wake 
and NREM bout numbers in the 15-day SF group were significantly higher than those in the 
baseline and corresponding EC group while NREM bout length was lower on Day 7 and Day 
15 (Fig. 1N-1P). A large number of Wake and NREM bouts but short NREM lengths indicate 
highly fragmented sleep. The EC group had no significant difference in the time spent in each 
sleep stage, the number of Wake and NREM bouts, and the NREM bout length compared to 
the baseline at all experimental periods, which shows well-preserved sleep continuity. 
3.2 Metabolic differences between SF and EC groups 
We performed multivariate statistical analysis and established a discrimination model 
(Fig. 2). The PCA and PLS-DA analysis showed group separation between SF and EC group, 
as well as clear discrimination on 4-day set and 15-day set (Fig. 2A and 2B). The PLS-DA 
analysis on SF and EC group from 4-day and 15-day showed much clear discrimination 
between 4-day SF and 4-day EC groups and 15-day SF and 15-day EC groups, with a Q2 
value of 0.782 (R2X = 0.594, R2Y = 0.988) and 0.797 (R2X = 0.621, R2Y = 0.905), 
respectively (Fig. 2C and 2D). The significantly changed metabolites were selected with the 
statistical significance based on p-value and false discovery rate (FDR) adjusted p-value. All 
the considered data sets were visualized for a substantial separation of the two groups of 
samples; for instance, 4-day SF vs. 4-day EC and 15-day SF vs. 15-day EC (Fig. 3). Based on 
metabolite selection criteria, 66 and 444 markers were selected from the 4-day and 15-day 
data sets, respectively.  
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3.3 Identification of metabolites significantly altered in SF groups 
Among the selected markers, total 10 key markers that contributed to group separation 
between the overall SF and EC groups were identified including adenosine monophosphate 
(AMP), glycerophosphocholine (GPCh), hypoxanthine, jasmonic acid, L-aspartate, L-
glutamate, L-methionine, L-tryptophan, myristoylcarnitine, and palmitoylcarnitine (PLC). 
Marker identification was performed by comparing the measured m/z value and the MS/MS 
fragmentation spectra of the main markers with the theoretical values of metabolites provided 
in the database (Supplementary Fig. 1 and Supplementary Table 1). The identified 
metabolites are summarized in Table 1 and represented in an S-plot (Fig. 4). According to the 
statistical significance based on p-value and FDR adjusted p-value, the metabolic changes in 
the 4-day group were neither so dramatic nor significant. Significant metabolic changes were 
observed only in the 15-day group. In the 15-day group, 9 markers were identified: adenosine 
monophosphate (AMP), glycerophosphocholine (GPCh), hypoxanthine, L-aspartate, L-
glutamate, L-methionine, L-tryptophan, myristoylcarnitine, and palmitoylcarnitine (PLC) 
(Fig. 4A). Among them, L-tryptophan (+0.749 fold), myristoylcarnitine (+0.913 fold), and 
PLC (+0.927 fold) were up-regulated in the SF group, while AMP (-0.750 fold), GPCh (-
7.543 fold), hypoxanthine (-1.472 fold), L-aspartate (-2.202 fold), L-glutamate (-0.727 fold), 
and L-methionine (-5.456 fold) were significantly down-regulated in the SF group compared 
with the EC group. The summary profiles of the individual metabolites altered in the 
hippocampus of the 4-day and 15-day SF groups compared to the corresponding EC groups 
are shown in Table 1. 
 
 
 
3.4 Metabolic pathway analysis 
Because a statistical significance was observed only in the 15-day groups, metabolites 
identified from the 15-day SF experiments were used for metabolic interpretation by pathway 
analysis using MetPa analysis through MetaboAnalyst. As shown in Fig. 5, alanine, aspartate, 
and glutamate metabolism was determined as the key metabolism important in the 15-day SF 
group. In addition, metabolic pathways involved in other amino acid metabolism, aminoacyl-
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tRNA biosynthesis, and nucleotides were metabolic pathways that were significantly altered 
in the 15-day SF group.  
 
4. Discussion 
In the present untargeted metabolomics study, we found that alanine, aspartate, and 
glutamate metabolism pathway is the most altered metabolic pathway in the 15-day SF group 
compared to the 15-day EC group. The 4-day SF group showed a typical pattern of SF in the 
EEG and clearly differentiated in the metabolites profiles on PCA or PLS-DA compared to 
the corresponding EC group, but the identified metabolites were not statistically significant. 
Indeed, only the 4-day SF group showed a significant decrease in REM sleep compared to 
those in the baseline and corresponding EC group. Thus, it is not possible to exclude the 
possibility that the reduced REM sleep, rather than the SF itself, may have affected the 
distinction of metabolites in the 4-day groups.     
Glutamate and aspartate are major excitatory neurotransmitters that can excite all 
neurons in the central nervous system including the hippocampal area (Fleck et al., 1993); 
however, excessive amounts of glutamate and aspartate can cause excitotoxicity through the 
NMDA receptor-dependent pathway. Glutamate level in hippocampi of sleep-restricted rats is 
likely to be affected by this type of SR and duration. In a study that examined glutamate level, 
6 or 12 h of SD produced a greater increase in glutamate level in the rat hippocampus and 
thalamus compared with control groups (Cortese et al., 2010). Interestingly, in our study, 
these excitatory neurotransmitters (aspartate and glutamate) showed a temporal variation in 
the levels according to the SF duration. Levels of aspartate and glutamate showed a tendency 
to increase in the 4-day SF group (acute condition), but these were significantly decreased in 
the 15-day SF group (chronic condition), implying that lowering of excitatory 
neurotransmitter levels in the hippocampus of sleep-fragmented rats could be a protective 
mechanism against excitotoxicity induced by frequent arousal. This possibility might be 
partially supported by the findings from Novati et al. showing that 30 days of SR induced by 
a rotating drum attenuated the loss of cholinergic neurons in the nucleus basalis 
magnocellularis (NBM) when a neurotoxic dose of NMDA was administered into the NBM, 
indicating activation of a protective mechanism such as desensitization following SR against 
NMDA-mediated neurotoxicity (Novati et al., 2012). Whether these phenomena are specific 
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events limited only to SF or can be generalized to any type of sleep disturbance requires 
further investigation. In addition to the role as a neurotransmitter, L-aspartate has a central 
effect on the stress responses. Intracerebroventricular injection of L-aspartate and its 
derivatives attenuated the stress response induced by social isolation (Erwan et al., 2012). To 
the best of our knowledge, aspartate level has not been determined in hippocampi of rats 
subjected to SF; however, the paradoxical SD (PSD) model using the multiple platform 
method, which also induces SF, 72-h of PSD increased aspartate in the rat hippocampus 
(Mohammed et al., 2011). Although not statistically significant, similar increases in aspartate 
levels were observed in the 4-day SF group. Therefore, it can be inferred that the stress 
response induced by SF in the hippocampus may show a temporal variation with the duration 
of SF and depend on the level of aspartate. To demonstrate this hypothesis, a functional study 
of the role of L-aspartate on the stress response in SF conditions is needed. 
     In the present study, up-regulation in tryptophan metabolism was observed in the 15-
day SF group. The tryptophan level in the hippocampus increases under various stress 
conditions due to the increase in demand for 5-HT as a response to stress (Hery et al., 1970). 
In a previous study, increased 5-HT level was observed in the rat ventral hippocampal 
region following restriction of 21-days of rapid eye movement (REM) (da Silva Rocha-
Lopes et al., 2017). This implies that increased tryptophan metabolism in the SF group can 
play a role in compensating for stress caused by frequent sleep interruption. In addition, 
tryptophan is a melatonin precursor, an important sleep-inducing hormone. However, the 
hippocampus is not a brain region directly associated with sleep induction; thus, the role of 
tryptophan as a sleep homeostatic regulator in rats subjected to SF is inconclusive. 
Melatonin also reduces the activity of the hippocampus and suppresses long-term 
potentiation induction (Ozcan et al., 2006; Wang et al., 2005).  
PLC and Myristoylcarnitine belonging to long-chain acyl derivatives of carnitine also 
increased in the SF group. PLC can regulate the expression or activity of specific signaling 
molecules/apoptosis-related proteins/neurotransmission-related proteins (Mutomba et al., 
2000; Sobiesiak-Mirska et al., 2003). PLC also plays an important role in the synthesis of 
lipids involved in neural membranes, brain plasticity, and downstream signal transduction 
(Jones et al., 2010). Currently, the biological function of myristoylcarnitine is not well 
known.  
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Hypoxanthine is an important purine derivative related to the purine salvage pathway 
in the brain, a pathway to convert bases and nucleosides salvaged from dietary sources and 
tissue breakdown back into purine nucleotides. Although the reason for decreased 
hypoxanthine level in the SF group is unknown, one possible explanation is to maintain 
brain energy homeostasis imbalanced by frequent arousals. ATP is released from the 
synaptic terminal of neurons due to neuronal activity and released into extracellular space. 
Released ATP and adenosine, a degraded form of ATP, bind to purine type 2 receptors and 
to adenosine type 1 receptors expressed on glia (Fields and Burnstock, 2006), respectively, 
resulting in the release of pro-inflammatory cytokines such as tumor necrosis factor and 
interleukin-1β, thereby promoting sleep. Maintaining brain energy levels is considered the 
main function of sleep (Krueger et al., 2016; Scharf et al., 2008). Thus, the hypoxanthine 
level in the SF group may be reduced to compensate for energy consumption caused by 
increased neuronal activity through recycling of ATP.  
We observed reduced AMP level in the SF group. AMP is a nucleotide used as a 
monomer in DNA and RNA and is composed of a phosphate group, sugar ribose, and 
adenine nucleobase. Decreases in AMP level were found in the Alzheimer mouse model 
(Esteve et al., 2017). AMP can exist in the form of a cyclic structure, cAMP. The principal 
target for cAMP is cAMP-dependent protein kinase A (PKA) whose activity is dependent 
on cellular levels of cAMP. It has been known that cAMP/PKA signaling has a pivotal role 
in hippocampus-dependent memory (Abel and Nguyen, 2008). Thus, a reduced AMP level 
might reflect a decrease in the reservoir that restores ATP levels and may reflect the 
functional attenuation of hippocampal-dependent memory induced by cAMP/PKA 
signaling.  
L-methionine was also decreased in the hippocampus of rats subjected to chronic SF. 
According to a previous study, methionine level is likely associated with stress-induced 
cognitive impairments (Naninck et al., 2017). In that study, methionine level was decreased 
in brains of mice exposed to early-life stress (ES), and its supplementation restored 
methionine level and ES-induced cognitive impairments. In another study, long-term 
dietary restriction of methyl-donors including methionine, choline, and folic acid impaired 
hippocampus-dependent memory in mice, accompanying CpG hypermethylation of the 
specific gene promoter region in the hippocampus (Tomizawa et al., 2015). In addition, 
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methionine is an acetylcholine precursor. Acetylcholinesterase (AChE) activity, a crucial 
enzyme that hydrolyzes acetylcholine, was increased in hippocampi of mice subjected to 
dietary restriction of methionine (Vucevic et al., 2016). Because methionine is an 
acetylcholine precursor and its deficiency resulted in increased activation of AChE, a 
decrease in methionine level in the hippocampus of rats subjected to SF may indicate the 
impaired status of cholinergic neurotransmission in hippocampus subjected to long-term SF.  
GPCh showed the greatest reduction in the SF group. Choline is a precursor of 
acetylcholine, which is an important neurotransmitter for brain cognitive functions such as 
learning and memory (Fadda et al., 2000; Hasselmo, 2006). When choline intake is restricted 
due to a choline-deficient diet, AChE activity and (Na+, K+, and Mg2+) ATPase activity were 
differentially activated in the hippocampus, hypothalamus, cerebellum, and pons (Liapi et al., 
2009). These findings indicate the modulating roles of choline in cholinergic 
neurotransmission, neural excitability, and Mg2+ homeostasis in the brain. Whether GPCh has 
an important role by itself or as choline storage is unknown, but reductions of GPCh, similar 
to decreased methionine, likely reflect impaired cholinergic neurotransmission observed in 
the chronic SF group, possibly resulting in hippocampus-dependent learning and memory 
impairment.  
Some limitations of our study should be addressed. First, we evaluated the metabolite 
profile of the whole hippocampus. It was therefore impossible to distinguish whether these 
compounds and amino acids were inside or outside the hippocampus cells. The analysis of 
metabolites from tissue samples can be influenced by mixing the intracellular and 
extracellular levels and the disturbance by intracellular enzymes which rapidly degrade the 
target substance. However, untargeted metabolomics of whole tissue sample are generally not 
intended to distinguish the inner and outer metabolites of the cell. An additional experiment, 
such as flux analysis using isotope labeled tracer, is needed to determine the origin of 
metabolites altered by SF. Second, there was no home cage control group in the present study. 
We used exercise group which offers the same amount of walking distance as the rats in the 
SF group, but continuous movement lasting 10 minute without a pause in the EC group may 
affect metabolite profiles of the hippocampus.   
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In this untargeted metabolomics study, significantly altered metabolic pathways and 
metabolite profiles were observed in the hippocampi of rats subjected to chronic SF. The 
altered pathways and metabolite profiles varied according to the duration of SF. Further 
studies are required to clarify the biological meanings or functions of these metabolites in 
hippocampi of rats subjected to SF to understand the impact of SF on hippocampus-
dependent neurocognitive behavior.  
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Figure legends 
Figure 1. Schematic representation of the experimental protocols for SF and EC 
procedures, comparison of body weight, and effects of 4 days’ and 15 days’ SF or EC on 
sleep parameters.  
A. Experimental protocol for the 4-day experiment. Prior to SF or EC, animals were placed in 
an individual wheel for 7 days to acclimate to the novel environment. B. Experimental 
protocol for the 15-day experiment. C. Average body weight (g) of 4-day group at baseline 
and on Day 4. D. Average body weight (g) of 15-day group at baseline and on Day 15. E. 
Comparison of time spent in Wake (%) between baseline and follow-up or between 4-day EC 
and SF groups (n=4, each). F. Comparison of time spent in NREM (%) between baseline and 
follow-up or between 4-day EC and SF groups. G. Comparison of time spent in REM (%) 
between baseline and follow-up or between 4-day EC and SF groups. H. Assessments of 
mean Wake bout number between baseline and follow-up or between 4-day EC and SF 
groups. I. Assessments of mean NREM bout number between baseline and follow-up or 
between 4-day EC and SF groups. J. Assessments of mean NREM bout length between 
baseline and follow-up or between 4-day EC and SF groups. K. Comparison of time spent in 
Wake (%) between baseline and follow-up or between 15-day EC and SF groups (n=4, each). 
L. Comparison of time spent in NREM (%) between baseline and follow-up or between 15-
day EC and SF groups. M. Comparison of time spent in REM (%) between baseline and 
follow-up or between 15-day EC and SF groups. N. Assessments of mean Wake bout number 
between baseline and follow-up or between 15-day EC and SF groups. O. Assessments of 
mean NREM bout number between baseline and follow-up or between 15-day EC and SF 
groups. P. Assessments of mean NREM bout length between baseline and follow-up or 
between 15-day EC and SF groups. B, baseline; EC, exercise control; SF, sleep fragmentation; 
NREM, non-rapid eye movement; REM, rapid eye movement. *P<0.05 vs. baseline, 
determined by paired t-test; †P<0.05 vs. corresponding EC group, determined by independent 
t-test.  
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Figure 2. Difference in metabolite profiles between SF and EC groups. 
Principle component analysis (PCA) and Partial least square discrimination analysis (PLS-
DA) score plots of metabolite profiles from rat hippocampi in the SF and EC groups. PCA 
and PLS-DA score plots derived from untargeted metabolite profiling of hippocampus were 
analyzed by LC/MS. Each symbol represents the metabolomics profile of an individual 
sample. A. Comparison of SF and EC group from 4-day (black) and 15-day (red) by PCA. B. 
Comparison of SF (open boxes and triangles) and EC (squares and triangles) group from 4-
day (black) and 15-day (red) by PLS-DA. C. Discrimination of metabolic profiles between 4-
day SF (red triangles) and 4-day EC (black squares) groups by PLS-DA. D. Discrimination of 
metabolic profiles between 15-day SF (red triangles) and 15-day EC (black squares) groups 
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by PLS-DA. SF, sleep fragmentation; EC, exercise control.  
 
Figure 3. Differently expressed level of metabolites by SF 
Differently expressed metabolites levels from 4-day (A) and 15-day (B) were presented 
including AMP, L-aspartate, L-glutamate, GPCh, hypoxanthine, jasmonic acid, L-methionine, 
myristoylcarnitine, PLC, and L-tryptophan. Y-axis represents relative intensity from LC/MS 
detection. SF, sleep fragmentation; EC, exercise control; PLC, palmitoylcarnitine; AMP, 
adenosine monophosphate; GPCh, glycerophosphocholine. *FDR adjusted P<0.05; **FDR 
adjusted P <0.001; ***FDR adjusted P <0.00001. 
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Figure 4. Identification of differentially expressed metabolites between SF and EC 
groups.  
To identify differentially expressed metabolites between SF and EC groups, S-plot analysis 
was performed. Potential marker signals that were significantly biased across the two groups 
are enclosed in red-color boxes. A. Differentiation of contributing signals between 4-day SF 
and 4-day EC groups. B. Differentiation of contributing signals between 15-day SF and 15-
day EC groups. The upper right panel shows contributing metabolites in the SF group and the 
lower left panel in the EC group. L-Asp, L-aspartate; L-Trp, L-tryptophan; AMP, adenosine 
monophosphate; L-Glu, L-glutamate; L-Met, L-methionine. 
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Figure 5. The analysis results of metabolic pathways significantly altered in the 15-day 
SF group.   
MetPa analysis was performed to determine metabolic pathways affected by SF. Metabolites 
from comparison between 15-day SF and 15-day EC groups were used to draw pathway 
contributions using MetPa analysis. The pathway impact values on X-axis were results from 
pathway topology analysis and y-axis values present a view of all the matched pathways 
arranged by p-values (pathway enrichment analysis). Each different radius sizes indicates the 
number of metabolites matched on the pathway and colors from beige to red is matched with 
p-value from pathway enrichment analysis. Therefore, alanine, aspartate, and glutamate 
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metabolism is the most important pathway. 1, Alanine, aspartate, and glutamate metabolism; 
2, Aminoacyl-tRNA biosynthesis; 3, Nitrogen metabolism; 4, D-glutamine and D-glutamate 
metabolism; 5, Purine metabolism; 6, Arginine and proline metabolism; 7, Cysteine and 
methionine metabolism; 8, Histidine metabolism; 9, Glycine, serine and threonine 
metabolism; 10; Tryptophan metabolism. 
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Table 
 
Table 1. Metabolite profiles identified in the 4-day SF and 15-day SF groups based on 
LC/MS analysis  
  
Jo
urn
al 
Pre
-pr
oo
f
30 
 
Table 1. Metabolite profiles identified in the 4-day SF and 15-day SF groups based on LC/MS 
analysis  
4-day SF 
Identification Measured m/z RT (min) P-value 
FDR adjusted  
P-value 
Fold change  
compared with EC 
Jasmonic acid 211.17522 14.68 4.674E-03 0.0511 0.556 
L-aspartate 134.08177 3.39 4.494E-03 0.0511 0.602 
L-glutamate 148.08522 2.74 1.807E-03 0.0683 0.121 
Lipoamide 189.1447 14.67 7.246E-03 0.0511 0.553 
15-day SF 
Metabolites Measured m/z RT (min) P-value 
FDR adjusted  
P-value 
Fold change  
compared with EC 
AMP 348.21896 2.83 1.972E-03 1.577E-04 - 0.750 
GPCh 258.22021 2.72 1.552E-08 2.021E-07 - 7.543 
Hypoxanthine 137.10307 4.11 2.250E-05 4.812E-07 - 1.472 
L-aspartate 134.08177 3.39 8.481E-05 9.110E-06 - 2.202 
L-glutamate 148.08522 2.74 3.298E-06 2.303E-06 - 0.727 
L-methionine 150.12025 3.33 3.942E-05 2.330E-06 - 5.456 
L-tryptophan 205.16923 8.74 2.497E-09 8.629E-09  0.749 
Myristoylcarnitine 372.5415 26.64 4.689E-07 1.118E-05  0.913 
PLC 400.58891 27.18 1.426E-10 2.300E-08  0.927 
SF, sleep fragmentation; EC, exercise control; LC/MS, liquid chromatography/mass spectrometry; 
m/z, mass-to-charge ratio; RT, retention time; PLC, palmitoylcarnitine; AMP, adenosine 
monophosphate; GPCh, glycerophosphocholine  
The fold change values are from area-normalized peak intensities and calculated by following formula: 
(SF-EC)/SF. Negative values represent decreases and positive values represent increases. All the 
LC/MS-identified metabolites with significant changes are included. P-values and the FDR adjusted 
P-value were used for metabolites selection. 
 
 
